U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C8H8O3
Molecular Weight 152.1473
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROXYTOLUIC ACID

SMILES

CC1=C(O)C(=CC=C1)C(O)=O

InChI

InChIKey=WHSXTWFYRGOBGO-UHFFFAOYSA-N
InChI=1S/C8H8O3/c1-5-3-2-4-6(7(5)9)8(10)11/h2-4,9H,1H3,(H,10,11)

HIDE SMILES / InChI

Description

Hydroxytoluic acid is a long-acting derivative of salicylate with antilipidemic properties. It shows fibrinolytic activity in human plasma by activating the fibrinolytic system and has been shown to lower plasma free fatty acid, cholesterol levels, and to raise metabolic oxygen consumption.

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Diabetic geriatric patients received 900 mg Hydroxytoluic acid orally as a single dose or as a daily dose of up to 2.7g/day for 3 months. For patients receiving a single dose a 50 g glucose tolerance test was performed 2 hours after dosing, for longitudinal patients the glucose tolerance test was performed monthly or every two months. After a single 900 mg dose, plasma insulin levels showed considerable increases, plasma free fatty acid fell 2 hours after dosing with hydroxytoluic acid. Daily dosing of 1.8 g/day hydroxytoluic acid as the sole treatment allowed patients to control their diabetes but was not significantly different from controls. When added to the existing drug regimen patients receiving hydroxy toluic acid showed a smoothing of control of blood sugar with decreased needs of insulin or sulphonylurea.
Route of Administration: Oral
In Vitro Use Guide
Unknown